Cargando…

PAI‐1 induces Src inhibitor resistance via CCL5 in HER2‐positive breast cancer cells

Tyrosine kinase Src is overexpressed and activated in various tumors, including breast cancer, and is supposed to promote cancer formation and development. Src inhibitors have been developed recently and have shown efficacy in breast cancer as a single agent or in combination with anti‐HER2 antibodi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fang, Hehui, Jin, Juan, Huang, Doudou, Yang, Fang, Guan, Xiaoxiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5989873/ https://www.ncbi.nlm.nih.gov/pubmed/29601121 http://dx.doi.org/10.1111/cas.13593

Ejemplares similares

Evaluation of Breast Cancer Stem Cells and Intratumor Stemness Heterogeneity in Triple-negative Breast Cancer as Prognostic Factors
por: Yang, Fang, et al.
Publicado: (2016)

Combined Inhibition of ATR and WEE1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer
por: Jin, Juan, et al.
Publicado: (2018)

Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma
por: Peiró, G, et al.
Publicado: (2014)

NCAPG confers trastuzumab resistance via activating SRC/STAT3 signaling pathway in HER2-positive breast cancer
por: Jiang, Lili, et al.
Publicado: (2020)

PAI-1 4G/5G Polymorphism Contributes to Cancer Susceptibility: Evidence from Meta-Analysis
por: Wang, Shangqian, et al.
Publicado: (2013)

CD40×HER2 bispecific antibody overcomes the CCL2-induced trastuzumab resistance in HER2-positive gastric cancer
por: Sun, Weilin, et al.
Publicado: (2022)

Analysis of different HER‐2 mutations in breast cancer progression and drug resistance
por: Sun, Zijia, et al.
Publicado: (2015)

Clinical implications of the coexpression of SRC1 and NANOG in HER-2-overexpressing breast cancers
por: Jin, Chengyan, et al.
Publicado: (2016)

Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas.
por: Bouchet, C., et al.
Publicado: (1994)

ST5 Positively Regulates Osteoclastogenesis via Src/Syk/Calcium Signaling Pathways
por: Kim, Min Kyung, et al.
Publicado: (2019)

Novel Src/Abl tyrosine kinase inhibitor bosutinib suppresses neuroblastoma growth via inhibiting Src/Abl signaling
por: Bieerkehazhi, Shayahati, et al.
Publicado: (2016)

Correlation of Serum Levels of Urokinase Activation Plasminogen (uPA) and Its Inhibitor (PAI-1) with Hormonal and HER-2 Status in the Early Invasive Breast Cancer
por: Pusina, Sadat
Publicado: (2018)

The potential of Src inhibitors
por: Elias, Daniel, et al.
Publicado: (2015)

PGF2α-FP Receptor Ameliorates Senescence of VSMCs in Vascular Remodeling by Src/PAI-1 Signal Pathway
por: Hu, Bo-ang, et al.
Publicado: (2022)

The prognostic value of quantitative analysis of CCL5 and collagen IV in luminal B (HER2−) subtype breast cancer by quantum-dot-based molecular imaging
por: Zhu, Yong-yun, et al.
Publicado: (2018)

Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines
por: Stanley, Aryan, et al.
Publicado: (2017)

Association of uPA and PAI-1 tumor levels and 4G/5G variants of PAI-1 gene with disease outcome in luminal HER2-negative node-negative breast cancer patients treated with adjuvant endocrine therapy
por: Jevrić, Marko, et al.
Publicado: (2019)

Impact of uPA/PAI-1 and disseminated cytokeratin-positive cells in breast cancer
por: Märkl, Bruno, et al.
Publicado: (2019)

CCL5 mediates target‐kinase independent resistance to FLT3 inhibitors in FLT3‐ITD‐positive AML
por: Waldeck, Silvia, et al.
Publicado: (2020)

The role of irreversible pan-HER tyrosine kinase inhibitors in the treatment of HER2-Positive metastatic breast cancer
por: Wu, Zihong, et al.
Publicado: (2023)

Pim1 Kinase Inhibitors Exert Anti-Cancer Activity Against HER2-Positive Breast Cancer Cells Through Downregulation of HER2
por: Wang, Bo-Wei, et al.
Publicado: (2021)

Tyrosine Kinase Inhibitors in the Combination Therapy of HER2 Positive Breast Cancer
por: Yang, Xue, et al.
Publicado: (2020)

HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now
por: Schlam, Ilana, et al.
Publicado: (2021)

Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer
por: Singh, Desh Deepak, et al.
Publicado: (2022)

Pyrotinib Sensitizes 5-Fluorouracil-Resistant HER2(+) Breast Cancer Cells to 5-Fluorouracil
por: Yi, Jianing, et al.
Publicado: (2020)

The Correlation Between PARP1 and BRCA1 in AR Positive Triple-negative Breast Cancer
por: Luo, Jiayan, et al.
Publicado: (2016)

Myeloid-Derived Suppressor Cells Alleviate Renal Fibrosis Progression via Regulation of CCL5-CCR5 Axis
por: Qiu, Yue, et al.
Publicado: (2021)

Discovery of a Potential HER2 Inhibitor from Natural Products for the Treatment of HER2-Positive Breast Cancer
por: Li, Jianzong, et al.
Publicado: (2016)

Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity
por: Wilson, G R, et al.
Publicado: (2006)

CC chemokines CCL2, CCL3, CCL4 and CCL5 are elevated in osteoporosis patients
por: Farangis, Fatehi, et al.
Publicado: (2017)

The Transmodulation of HER2 and EGFR by Substance P in Breast Cancer Cells Requires c-Src and Metalloproteinase Activation
por: Garcia-Recio, Susana, et al.
Publicado: (2015)

Plasminogen activator inhibitor-1 (PAI-1) is not related to response to neoadjuvant chemotherapy in breast cancer.
por: Pierga, J. Y., et al.
Publicado: (1997)

País que fue será /
por: Gelman, Juan, 1930-
Publicado: (2004)

Role of estrogen receptors and Src signaling in mechanisms of bone metastasis by estrogen receptor positive breast cancers
por: Chiu, Jen-Hwey, et al.
Publicado: (2017)

Antibody-drug conjugates in HER2-positive breast cancer
por: Li, Lixi, et al.
Publicado: (2022)

Role of 4G/5G plasminogen activator inhibitor-1 (PAI-1) gene polymorphism and the PAI-1 plasma levels in the outcome of patients with severe sepsis
por: Lorente, L, et al.
Publicado: (2009)

Loss of Integrin-Linked Kinase Sensitizes Breast Cancer to SRC Inhibitors
por: Beetham, Henry, et al.
Publicado: (2022)

El País.
Publicado: (1983)

País portátil
por: González León, Adriano
Publicado: (1969)

Corrigendum: Myeloid-Derived Suppressor Cells Alleviate Renal Fibrosis Progression via Regulation of CCL5-CCR5 Axis
por: Qiu, Yue, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_79oi1mhi6eohm97ig0b11sne3i